TSG101 and PEG10 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of the gallbladder

Oncology Letters

Volumn 7, Issue 4, 2014, Pages 1128-1138

  Liu, Ziru ^a   Yang, Zhulin ^a   Liu, Dongcai ^a   Li, Daiqiang ^a   Zou, Qiong ^b   Yuan, Yuan ^b   Li, Jinghe ^b   Liang, Lufeng ^c   Chen, Meigui ^d   Chen, Senlin ^e  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Hunan Provincial Second People s Hospital   (China)

^d Loudi Central Hospital   (China)

^e HUNAN CANCER HOSPITAL   (China)

Author keywords

Adenocarcinoma; Adenosquamous carcinoma; Gallbladder cancer; Metastasis; PEG10; Prognosis; Squamous cell carcinoma; TSG101

Indexed keywords

TUMOR SUSCEPTIBILITY GENE 101 PROTEIN;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; GALLBLADDER CARCINOMA; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATERNALLY EXPRESSED GENE; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION; TUMOR SUSCEPTIBILITY GENE 101;

EID: 84896695931     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1886     Document Type: Article

References (31)

1. Azad MB, Chen Y and Gibson SB: Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal 11: 777-790, 2009.
2. Pelicano H, Carney D and Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7: 97-110, 2004.
3. Storz P: Reactive oxygen species in tumor progression. Front Biosci 10: 1881-1896, 2005.
4. Brigelius-Flohé R and Kipp A: Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys Acta 1790: 1555-1568, 2009.
5. Wiseman H and Halliwell B: Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 313: 17-29, 1996.
6. Leto TL and Geiszt M: Role of Nox family NADPH oxidases in host defense. Antioxid Redox Signal 8: 1549-1561, 2006.
7. Cullen JJ, Mitros FA and Oberley LW: Expression of antioxidant enzymes in diseases of the human pancreas: another link between chronic pancreatitis and pancreatic cancer. Pancreas 26: 23-27, 2003.
8. Ono R, Kobayashi S, Wagatsuma H, et al: A retrotransposon-derived gene, PEG10, is a novel imprinted gene located on human chromosome 7q21. Genomics 73: 232-237, 2001.
9. Okabe H, Satoh S, Furukawa Y, et al: Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res 63: 3043-3048, 2003.
10. Kainz B, Shehata M, Bilban M, et al: Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. Int J Cancer 121: 1984-1993, 2007.
11. Tsuji K, Yasui K, Gen Y, et al: PEG10 is a probable target for the amplification at 7q21 detected in hepatocellular carcinoma. Cancer Genet Cytogenet 198: 118-125, 2010.
12. Chunsong H, Yuling H, Li W, et al: CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells. J Immunol 177: 6713-6722, 2006.
13. Li CM, Margolin AA, Salas M, et al: PEG10 is a c-MYC target gene in cancer cells. Cancer Res 66: 665-672, 2006.
14. Ip WK, Lai PB, Wong NL, et al: Identification of PEG10 as a progression related biomarker for hepatocellular carcinoma. Cancer Lett 250: 284-291, 2007.
15. Jie X, Lang C, Jian Q, et al: Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells. Oncogene 26: 5741-5751, 2007.
16. Lux A, Beil C, Majety M, et al: Human retroviral gag-and gag-pol-like proteins interact with the transforming growth factor-beta receptor activin receptor-like kinase 1. J Biol Chem 280: 8482-8493, 2005.
17. Ono R, Nakamura K, Inoue K, et al: Deletion of Peg10, an imprinted gene acquired from a retrotransposon, causes early embryonic lethality. Nat Genet 38: 101-106, 2006.
18. Li L and Cohen SN: Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 85: 319-329, 1996.
19. Young TW, Rosen DG, Mei FC, et al: Up-regulation of tumor susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in ovarian cancer. Clin Cancer Res 13: 3848-3854, 2007.
20. Bashirova AA, Bleiber G, Qi Y, et al: Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1. J Virol 80: 6757-6763, 2006.
21. Liu RT, Huang CC, You HL, et al: Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas. Oncogene 21: 4830-4837, 2002.
22. Koon N, Schneider-Stock R, Sarlomo-Rikala M, et al: Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53: 235-240, 2004.
23. Ma XR, Edmund Sim UH, Pauline B, et al: Overexpression of WNT2 and TSG101 genes in colorectal carcinoma. Trop Biomed 25: 46-57, 2008.
24. Zhu G, Gilchrist R, Borley N, et al: Reduction of TSG101 protein has a negative impact on tumor cell growth. Int J Cancer 109: 541-547, 2004.
25. Li L, Liao J, Ruland J, et al: A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc Natl Acad Sci USA 98: 1619-1624, 2001.
26. Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH and Fong Y: Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol 11: 310-315, 2004.
27. Roa JC, Tapia O, Cakir A, Basturk O, Dursun N, Akdemir D, Saka B, Losada H, Bagci P and Adsay NV: Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas. Mod Pathol 24: 1069-1078, 2011.
28. Kondo M, Dono K, Sakon M, et al: Adenosquamous carcinoma of the gallbladder. Hepatogastroenterology 49: 1230-1234, 2002.
29. Muzio G, Maggiora M, Paiuzzi E, Oraldi M and Canuto RA: Aldehyde dehydrogenases and cell proliferation. Free Radic Biol Med 52: 735-746, 2012.
30. Zhao Y, You H, Liu F, et al: Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. Cancer Lett 185: 211-218, 2002.
31. Shen H, Pan Y, Han Z, et al: Reversal of multidrug resistance of gastric cancer cells by downregulation of TSG101 with TSG101siRNA. Cancer Biol Ther 3: 561-565, 2004.